Meanwhile, several prior studies targeting ACS and ASCVD populations have verified the role of PCSK9 inhibitors in lowering cardiovascular risk (46–48), strongly supporting the conclusions of this study. This evidence concerns the gene PCSK9 and atherosclerosis.